Detection of the NS3 Q80K polymorphism by Sanger and deep sequencing in hepatitis C virus genotype 1a strains in the UK

Clinical Microbiology and Infection

Volumn 21, Issue 11, 2015, Pages 1033-1039

  Beloukas, A ^a   King, S ^a   Childs, K ^b   Papadimitropoulos, A ^a   Hopkins, M ^c   Atkins, M ^d   Agarwal, K ^b   Nelson, M ^e   Geretti, A M ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^d FRIMLEY PARK HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^e CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Lineage; NS3; Protease inhibitors; Q80K; Simeprevir

Indexed keywords

NS3 PROTEASE; PROTEINASE; UNCLASSIFIED DRUG; VIRUS ENZYME; VIRUS RNA; NS3 PROTEIN, HEPATITIS C VIRUS; VIRUS PROTEIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CODON; DEEP SEQUENCING; ENZYME POLYMORPHISM; EUROPE; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENETIC ANALYZER; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HEPATITIS C VIRUS SUBTYPE 1A; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MAJOR CLINICAL STUDY; MALE; NEXT GENERATION SEQUENCING; NORTH AMERICA; NUCLEOTIDE SEQUENCE; PHYLOGENY; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SANGER SEQUENCING; UNITED KINGDOM; VIRUS LOAD; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; CLASSIFICATION; CLUSTER ANALYSIS; DNA SEQUENCE; GENETICS; GENOTYPE; GREAT BRITAIN; HEPACIVIRUS; HEPATITIS C, CHRONIC; HETEROZYGOTE; HIGH THROUGHPUT SEQUENCING; ISOLATION AND PURIFICATION; MISSENSE MUTATION; VIROLOGY;

ADULT; AMINO ACID SUBSTITUTION; CARRIER STATE; CLUSTER ANALYSIS; DRUG RESISTANCE, VIRAL; GENOTYPE; GREAT BRITAIN; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION, MISSENSE; PHYLOGENY; PREVALENCE; RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84945466065     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2015.07.017     Document Type: Article

References (29)

1. Cento V., Mirabelli C., Salpini R., Dimonte S., Artese A., Costa G., et al. Hcv genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PloS One 2012, 7:e39652.
2. Bae A., Sun S.C., Qi X., Chen X., Ku K., Worth A., et al. Susceptibility of treatment-naive hepatitis c virus (hcv) clinical isolates to hcv protease inhibitors. Antimicrob Agents Chemother 2010, 54:5288-5297.
3. Bartels D.J., Sullivan J.C., Zhang E.Z., Tigges A.M., Dorrian J.L., De Meyer S., et al. Hepatitis c virus variants with decreased sensitivity to direct-acting antivirals (daas) were rarely observed in daa-naive patients prior to treatment. J Virol 2013, 87:1544-1553.
4. Berger K.L., Triki I., Cartier M., Marquis M., Massariol M.J., Bocher W.O., et al. Baseline hepatitis c virus (hcv) ns3 polymorphisms and their impact on treatment response in clinical studies of the hcv ns3 protease inhibitor faldaprevir. Antimicrob Agents Chemother 2014, 58:698-705.
5. Kuntzen T., Timm J., Berical A., Lennon N., Berlin A.M., Young S.K., et al. Naturally occurring dominant resistance mutations to hepatitis c virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 2008, 48:1769-1778.
6. Leggewie M., Sreenu V.B., Abdelrahman T., Leitch E.C., Wilkie G.S., Klymenko T., et al. Natural ns3 resistance polymorphisms occur frequently prior to treatment in hiv-positive patients with acute hepatitis c. AIDS 2013, 27:2485-2488.
7. Morel V., Duverlie G., Brochot E. Patients eligible for treatment with simeprevir in a french center. J Clin Virol: the official publication of the Pan American Society for Clinical Virology 2014, 61:149-151.
8. Sarrazin C., Lathouwers E., Peeters M., Daems B., Buelens A., Witek J., et al. Prevalence of the hepatitis c virus ns3 polymorphism q80k in genotype 1 patients in the european region. Antiviral Res 2015, 116C:10-16.
9. Vicenti I., Rosi A., Saladini F., Meini G., Pippi F., Rossetti B., et al. Naturally occurring hepatitis c virus (hcv) ns3/4a protease inhibitor resistance-related mutations in hcv genotype 1-infected subjects in Italy. J Antimicrob Chemother 2012, 67:984-987.
10. Jabara C.B., Hu F., Mollan K.R., Williford S.E., Menezes P., Yang Y., et al. Hepatitis c virus (hcv) ns3 sequence diversity and antiviral resistance-associated variant frequency in hcv/hiv coinfection. Antimicrob Agents Chemother 2014, 58:6079-6092.
11. Lenz O., Verbinnen T., Lin T.I., Vijgen L., Cummings M.D., Lindberg J., et al. In vitro resistance profile of the hepatitis c virus ns3/4a protease inhibitor tmc435. Antimicrob Agents Chemother 2010, 54:1878-1887.
12. Forns X., Lawitz E., Zeuzem S., Gane E., Bronowicki J.P., Andreone P., et al. Simeprevir with peginterferon and ribavirin leads to high rates of svr in patients with hcv genotype 1 who relapsed after previous therapy: A phase 3 trial. Gastroenterology 2014, 146:1669-1679 e1663.
13. Jacobson I.M., Dore G.J., Foster G.R., Fried M.W., Radu M., Rafalsky V.V., et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis c virus genotype 1 infection (quest-1): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014, 384:403-413.
14. Manns M., Marcellin P., Poordad F., de Araujo E.S., Buti M., Horsmans Y., et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis c virus genotype 1 infection (quest-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014, 384:414-426.
15. Simeprevir summary of product characteristics. Available at: [accessed 3.03.15]. http://www.Ema.Europa.Eu/docs/en_gb/document_library/epar_-_product_information/human/002777/wc500167867.Pdf.
16. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J 2011, 17:10-12.
17. Verbist B.M., Thys K., Reumers J., Wetzels Y., Van der Borght K., Talloen W., et al. Virvarseq: A low-frequency virus variant detection pipeline for illumina sequencing using adaptive base-calling accuracy filtering. Bioinformatics 2015, 31:94-101.
18. Dierynck I., Thys K., Ghys A., Sullivan J.C., Kieffer T.L., Aerssens J., et al. Deep-sequencing analysis of the gene encoding the hepatitis c virus nonstructural 3-4a protease confirms a low prevalence of telaprevir-resistant variants at baseline and the end of the realize study. J Infect Dis 2014, 210:1871-1880.
19. Beloukas A., Magiorkinis E., Magiorkinis G., Zavitsanou A., Karamitros T., Hatzakis A., et al. Assessment of phylogenetic sensitivity for reconstructing hiv-1 epidemiological relationships. Virus Res 2012, 166:54-60.
20. Guindon S., Dufayard J.F., Lefort V., Anisimova M., Hordijk W., Gascuel O. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of phyml 3.0. Syst Biol 2010, 59:307-321.
21. Price M.N., Dehal P.S., Arkin A.P. Fasttree 2--approximately maximum-likelihood trees for large alignments. PloS One 2010, 5:e9490.
22. Gianella S., Delport W., Pacold M.E., Young J.A., Choi J.Y., Little S.J., et al. Detection of minority resistance during early hiv-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants. J Virol 2011, 85:8359-8367.
23. McCloskey R.M., Liang R.H., Joy J.B., Krajden M., Montaner J.S., Harrigan P.R., et al. Global origin and transmission of hepatitis c virus nonstructural protein 3 q80k polymorphism. J Infect Dis 2015, 211:1288-1295.
24. Pickett B.E., Striker R., Lefkowitz E.J. Evidence for separation of hcv subtype 1a into two distinct clades. J Viral Hepat 2011, 18:608-618.
25. Lawitz E., Sulkowski M.S., Ghalib R., Rodriguez-Torres M., Younossi Z.M., Corregidor A., et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis c virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the cosmos randomised study. Lancet 2014, 384:1756-1765.
26. McPhee F., Friborg J., Levine S., Chen C., Falk P., Yu F., et al. Resistance analysis of the hepatitis c virus ns3 protease inhibitor asunaprevir. Antimicrob Agents Chemother 2012, 56:3670-3681.
27. Pilot-Matias T., Tripathi R., Cohen D., Gaultier I., Dekhtyar T., Lu L., et al. In vitro and in vivo antiviral activity and resistance profile of the hepatitis c virus ns3/4a protease inhibitor abt-450. Antimicrob Agents Chemother 2015, 59:988-997.
28. Lenz O., Verbinnen T., Fevery B., Tambuyzer L., Vijgen L., Peeters M., et al. Virology analyses of hcv isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in phase iib/iii studies. J Hepatol 2015, 62:1008-1014.
29. Akuta N., Suzuki F., Sezaki H., Suzuki Y., Hosaka T., Kobayashi M., et al. Evolution of simeprevir-resistant variants over time by ultra-deep sequencing in hcv genotype 1b. J Med Virol 2014, 86:1314-1322.